Beijing SL Pharmaceutical Co Ltd (002038) - Total Assets
Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) holds total assets worth CN¥5.84 Billion CNY (≈ $854.10 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 002038 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Beijing SL Pharmaceutical Co Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 002038 net asset value for net asset value and shareholders' equity analysis.
Beijing SL Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Beijing SL Pharmaceutical Co Ltd's total assets of CN¥5.84 Billion consist of 34.5% current assets and 65.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.6% |
| Accounts Receivable | CN¥80.55 Million | 1.3% |
| Inventory | CN¥681.81 Million | 11.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.14 Billion | 18.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing SL Pharmaceutical Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing SL Pharmaceutical Co Ltd's current assets represent 34.5% of total assets in 2025, a decrease from 51.0% in 2001.
- Cash Position: Cash and equivalents constituted 8.6% of total assets in 2025, up from 4.8% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 13.0% in 2001.
- Asset Diversification: The largest asset category is intangible assets at 18.7% of total assets.
Beijing SL Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Beijing SL Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Beijing SL Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.38 | 7.67 | 7.38 |
| Quick Ratio | 2.47 | 6.46 | 6.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.44 Billion | CN¥2.23 Billion | CN¥2.05 Billion |
Beijing SL Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing SL Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 1.6% |
| Total Assets | CN¥6.07 Billion |
| Market Capitalization | $865.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing SL Pharmaceutical Co Ltd's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing SL Pharmaceutical Co Ltd's assets grew by 1.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing SL Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total assets of Beijing SL Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.07 Billion ≈ $888.54 Million |
+1.56% |
| 2024-12-31 | CN¥5.98 Billion ≈ $874.92 Million |
-4.76% |
| 2023-12-31 | CN¥6.28 Billion ≈ $918.63 Million |
+6.84% |
| 2022-12-31 | CN¥5.88 Billion ≈ $859.82 Million |
+2.00% |
| 2021-12-31 | CN¥5.76 Billion ≈ $842.94 Million |
+6.78% |
| 2020-12-31 | CN¥5.39 Billion ≈ $789.43 Million |
+3.25% |
| 2019-12-31 | CN¥5.22 Billion ≈ $764.58 Million |
+4.74% |
| 2018-12-31 | CN¥4.99 Billion ≈ $729.94 Million |
+8.79% |
| 2017-12-31 | CN¥4.59 Billion ≈ $670.94 Million |
+12.34% |
| 2016-12-31 | CN¥4.08 Billion ≈ $597.22 Million |
+8.50% |
| 2015-12-31 | CN¥3.76 Billion ≈ $550.44 Million |
+13.33% |
| 2014-12-31 | CN¥3.32 Billion ≈ $485.68 Million |
+22.38% |
| 2013-12-31 | CN¥2.71 Billion ≈ $396.87 Million |
+22.35% |
| 2012-12-31 | CN¥2.22 Billion ≈ $324.37 Million |
+27.68% |
| 2011-12-31 | CN¥1.74 Billion ≈ $254.05 Million |
+39.05% |
| 2010-12-31 | CN¥1.25 Billion ≈ $182.71 Million |
+22.43% |
| 2009-12-31 | CN¥1.02 Billion ≈ $149.23 Million |
+29.33% |
| 2008-12-31 | CN¥788.52 Million ≈ $115.38 Million |
+34.41% |
| 2007-12-31 | CN¥586.63 Million ≈ $85.84 Million |
+27.09% |
| 2006-12-31 | CN¥461.61 Million ≈ $67.55 Million |
+13.72% |
| 2005-12-31 | CN¥405.91 Million ≈ $59.40 Million |
+4.13% |
| 2004-12-31 | CN¥389.83 Million ≈ $57.04 Million |
+156.75% |
| 2003-12-31 | CN¥151.83 Million ≈ $22.22 Million |
+47.64% |
| 2002-12-31 | CN¥102.84 Million ≈ $15.05 Million |
+33.33% |
| 2001-12-31 | CN¥77.13 Million ≈ $11.29 Million |
-- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more